

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:57:48 ON 17 NOV 2010

=> file .pensee

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'CAPLUS' ENTERED AT 14:58:11 ON 17 NOV 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 14:58:11 ON 17 NOV 2010

FILE 'BIOSIS' ENTERED AT 14:58:11 ON 17 NOV 2010

Copyright (c) 2010 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 14:58:11 ON 17 NOV 2010

COPYRIGHT (C) 2010 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 14:58:11 ON 17 NOV 2010

Compendex Compilation and Indexing (C) 2010

Elsevier Engineering Information Inc (EEI). All rights reserved.

Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 14:58:11 ON 17 NOV 2010

COPYRIGHT (c) 2010 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 14:58:11 ON 17 NOV 2010

COPYRIGHT (C) 2010 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 14:58:11 ON 17 NOV 2010

COPYRIGHT (c) 2010 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 14:58:11 ON 17 NOV 2010

CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

=> e krahn thomas/au

E1	2	KRAHN T R/AU
E2	2	KRAHN THOAMS/AU
E3	138 -->	KRAHN THOMAS/AU
E4	11	KRAHN THOMAS A/AU
E5	2	KRAHN TIM/AU
E6	1	KRAHN TIMM H/AU
E7	4	KRAHN TIMOTHY/AU
E8	1	KRAHN TOBIAS/AU
E9	3	KRAHN U/AU
E10	4	KRAHN ULRICH G/AU
E11	7	KRAHN ULRIKE/AU
E12	38	KRAHN V/AU

=> s e2-e3

L1 140 ("KRAHN THOAMS"/AU OR "KRAHN THOMAS"/AU)

=> s l1 and masking

L2 16 L1 AND MASKING

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 16 DUP REM L2 (0 DUPLICATES REMOVED)

=> d l3 1-16 ti

L3 ANSWER 1 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking background fluorescence and luminescence in the optical
analysis of biomedical assays.

L3 ANSWER 2 OF 16 USPATFULL on STN
TI Use of Activators of Soluble Guanylate Cyclase for Treating Reperfusion
Damage

L3 ANSWER 3 OF 16 USPATFULL on STN
TI Use of Soluble Guanylate Cyclase Acitvators for Treating Acute and
Chronic Lung Diseases

L3 ANSWER 4 OF 16 USPATFULL on STN
TI Use of Activators of Soluble Guanylate Cyclase for Promoting Wound
Healing

L3 ANSWER 5 OF 16 USPATFULL on STN
TI Use of soluble guanylate cyclase activators for the treatment of
Raynaud's Phenomenon

L3 ANSWER 6 OF 16 USPATFULL on STN
TI MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L3 ANSWER 7 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking of the background fluorescence and luminescence in the
optical analysis of biomedical assays.

L3 ANSWER 8 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking background flourescence and luminescence in optical
analysis of biomedical assays.

L3 ANSWER 9 OF 16 USPATFULL on STN
TI Substituted alkyl uracils and thereof

L3 ANSWER 10 OF 16 USPATFULL on STN
TI Substituted amidoalkyl uracils and their use as inhibitors of the
poly(adp-ribose) synthetase (pars)

L3 ANSWER 11 OF 16 USPATFULL on STN
TI Masking of the background fluorescence and luminescence in the
optical analysis of biomedical assays

L3 ANSWER 12 OF 16 USPATFULL on STN
TI Substituted amidoalkyl-uracils and their use

L3 ANSWER 13 OF 16 USPATFULL on STN
TI MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
ANALYSIS OF BIOMEDICAL ASSAYS

L3 ANSWER 14 OF 16 USPATFULL on STN
TI Masking background fluorescence and luminescence in optical
analysis of biomedical assays

L3 ANSWER 15 OF 16 USPATFULL on STN
TI Masking of the background fluorescence and luminescence in the

optical analysis of biomedical assays

L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2010 ACS on STN
TI Masking background fluorescence and luminescence in optical
analysis of biomedical assays

=> d l3 1-5 ibib abs

L3 ANSWER 1 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2010:35759 BIOSIS <<LOGINID::20101117>>
DOCUMENT NUMBER: PREV201000035759
TITLE: Masking background fluorescence and luminescence
in the optical analysis of biomedical assays.
AUTHOR(S): Krahn, Thomas [Inventor]; Anonymous; Paffhausen,
Wolfgang [Inventor]; Schade, Andreas [Inventor]; Bechem,
Martin [Inventor]; Schmidt, Delf [Inventor]
CORPORATE SOURCE: Hagen, Germany
ASSIGNEE: Bayer Schering Pharma Aktiengesellschaft
PATENT INFORMATION: US 07615376 20091110
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (NOV 10 2009)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 30 Dec 2009
Last Updated on STN: 30 Dec 2009

AB In a process for the quantitative optical analysis of fluorescently
labelled biological cells 5, a cell layer on a transparent support at the
bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing
the fluorescent dye 4. The sensitivity of analytical detection can be
considerably improved if to the fluorescent dye 4 already present in
addition a masking dye 9, which absorbs the excitation light 6
for the fluorescent dye 4 and/or its emission light 7, is added to the
solution 3 and/or if a separating layer 10 permeable to the solution and
absorbing and/or reflecting the excitation light 6 or the emission light 7
is applied to the cell layer at the bottom 2. This process can also be
used for improving the sensitivity in the quantitative optical analysis of
a luminescent biological cell layer. The separating layer 10 must in this
case be composed such that it has a high power of reflection for the
luminescent light 11. Analogously, these process principles can also be
used in receptor studies for the masking of the interfering
background radiation in the quantitative optical analysis of fluorescently
or luminescently labelled reaction components. In this case, a receptor
layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a
solution (supernatant 3) in which a fluorescent or luminescent ligand 13
is dissolved. The sensitivity and accuracy of the analytical detection
can be considerably improved here if a masking dye 9 which
absorbs the excitation light 6 for the fluorescent dye and/or its emission
light or (in the case of luminescent ligands) the luminescent light is
added to the supernatant 3. Instead of the masking dye in the
solution 3 or optionally as an additional measure, a separating layer 10
permeable to the solution 3 and absorbing and/or reflecting the excitation
light 6 and/or the emission light or the luminescent light can be applied
to the cell or receptor layer 12 at the bottom 2.

L3 ANSWER 2 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2009:333904 USPATFULL <<LOGINID::20101117>>
TITLE: Use of Activators of Soluble Guanylate Cyclase for
Treating Reperfusion Damage
INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL

REPUBLIC OF
 Stasch, Johannes-peter, Solingen, GERMANY, FEDERAL
 REPUBLIC OF
 Weimann, Gerrit, Koln, GERMANY, FEDERAL REPUBLIC OF
 Thielemann, Wolfgang, Wuppertal, GERMANY, FEDERAL
 REPUBLIC OF
 PATENT ASSIGNEE(S): Bayer Health Care, Leverkusen, GERMANY, FEDERAL
 REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090298822	A1	20091203
APPLICATION INFO.:	US 2006-922838	A1	20060706 (11)
	WO 2006-EP6600		20060706
			20090803 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005031576	20050706
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	223	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to the use of compounds for manufacturing a pharmaceutical product/medicament for the prophylaxis and/or treatment of reperfusion damage.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 16 USPATFULL on STN
 ACCESSION NUMBER: 2009:320321 USPATFULL <<LOGINID::20101117>>
 TITLE: Use of Suluble Guanylate Cyclase Acitvators for
 Treating Acute and Chronic Lung Diseases
 INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL
 REPUBLIC OF
 Stasch, Johannes-peter, Solingen, GERMANY, FEDERAL
 REPUBLIC OF
 Weimann, Gerrit, Koln, GERMANY, FEDERAL REPUBLIC OF
 Thielemann, Wolfgang, Wuppertal, GERMANY, FEDERAL
 REPUBLIC OF
 PATENT ASSIGNEE(S): Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL
 REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090286781	A1	20091119
APPLICATION INFO.:	US 2006-83121	A1	20060923 (12)
	WO 2006-EP9264		20060923
			20090610 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005047946	20051006
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Barbara A. Shimei, Director, Patents & Licensing, Bayer	

HealthCare LLC - Pharmaceuticals, 555 White Plains
Road, Third Floor, Tarrytown, NY, 10591, US

NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 300

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of compounds of the formulae
I-VI for manufacturing a pharmaceutical for the treatment of acute and
chronic lung disorders such as the respiratory distress syndromes [acute
lung injury (ALI), acute respiratory distress syndrome (ARDS)] and the
treatment of COPD.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2009:246966 USPATFULL <<LOGINID::20101117>>
TITLE: Use of Activators of Soluble Guanylate Cyclase for
Promoting Wound Healing

INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL
REPUBLIC OF
Stasch, Johannes-Peter, Solingen, GERMANY, FEDERAL
REPUBLIC OF
Weimann, Gerrit, Koln, GERMANY, FEDERAL REPUBLIC OF
Thielemann, Wolfgang, Wuppertal, GERMANY, FEDERAL
REPUBLIC OF
Stelte-Ludwig, Beatrix, Wulfrath, GERMANY, FEDERAL
REPUBLIC OF

PATENT ASSIGNEE(S): Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL
REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090221573	A1	20090903
APPLICATION INFO.:	US 2006-988351	A1	20060706 (11)
	WO 2006-EP6598		20060706
			20090512 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005031575	20050706
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US	

NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 342

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for promoting wound healing by
administering one or more compounds identified in the claims, and to
pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2009:240402 USPATFULL <<LOGINID::20101117>>
TITLE: Use of soluble guanylate cyclase activators for the
treatment of Raynaud's Phenomenon

INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL

REPUBLIC OF
Stasch, Johannes-Peter, Solingen, GERMANY, FEDERAL
REPUBLIC OF
Weimann, Gerrit, Koln, GERMANY, FEDERAL REPUBLIC OF
Thielemann, Wolfgang, Wuppertal, GERMANY, FEDERAL
REPUBLIC OF
PATENT ASSIGNEE(S): Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL
REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090215769	A1	20090827
APPLICATION INFO.:	US 2006-988991	A1	20060704 (11)
	WO 2006-EP6501		20060704
			20090227 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005033370	20050716
	DE 2005-102005047945	20051006
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	218	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for prevention or treatment of primary and secondary Raynaud's phenomenon comprising administration of an effective amount of a compound selected from compounds of formulae I-IV, and to pharmaceutical compositions containing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 13 7-16 ibib abs

L3 ANSWER 7 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:111707 BIOSIS <<LOGINID::20101117>>
DOCUMENT NUMBER: PREV200700116299
TITLE: Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays.
AUTHOR(S): Anonymous; Krahn, Thomas [Inventor]; Paffhausen, Wolfgang [Inventor]; Schade, Andreas [Inventor]; Bechem, Martin [Inventor]; Schmidt, Delf [Inventor]
CORPORATE SOURCE: Hagen, Germany
ASSIGNEE: Bayer Healthcare AG
PATENT INFORMATION: US 07138280 20061121
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (NOV 21 2006)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Feb 2007
Last Updated on STN: 14 Feb 2007

AB In a process for the quantitative optical analysis of biological cells labelled with a fluorescent dye, the sensitivity of analytical detection can be considerably improved if a masking dye, which absorbs the excitation light for the fluorescent dye and/or its emission light is

added to the solution surrounding the biological cells and/or if a separating layer permeable to the solution and absorbing and/or reflecting the excitation light or the emission light is applied to a layer of the biological cells at the bottom of a reaction vessel. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components.

L3 ANSWER 8 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:8482 BIOSIS <<LOGINID::20101117>>
DOCUMENT NUMBER: PREV200700017950
TITLE: Masking background fluorescence and luminescence
in optical analysis of biomedical assays.
AUTHOR(S): Anonymous; Krahn, Thoams [Inventor]; Paffhausen,
Wolfgang [Inventor]; Schade, Andreas [Inventor]; Bechem,
Martin [Inventor]; Schmidt, Delf [Inventor]
CORPORATE SOURCE: Hagen, Germany
ASSIGNEE: Bayer Healthcare AG
PATENT INFORMATION: US 07063952 20060620
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (JUN 20 2006)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Dec 2006
Last Updated on STN: 20 Dec 2006

AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

L3 ANSWER 9 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2005:184036 USPATFULL <<LOGINID::20101117>>
TITLE: Substituted alkyl uracils and thereof

INVENTOR(S): Albrecht, Barbara, c/o Bayer Healthcare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF D 51368
Gerisch, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Harter, Michael, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Oehme, Felix, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schlemmer, Karl-Heinz, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Steinhagen, Henning, Sulzbach, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Bayer Healthcare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF, 51368 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050159431	A1	20050721
APPLICATION INFO.:	US 2003-501033	A1	20030103 (10)
	WO 2003-EP27		20030103

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10201240	20020115
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516, US	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1182	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel compounds of formula (I), to a method for the production thereof, and to their use as medicament active ingredients for the prophylaxis and/or treatment of diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2005:87882 USPATFULL <<LOGINID::20101117>>

TITLE: Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars)

INVENTOR(S): Albrecht, Barbara, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
Gerisch, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Handke-Erguden, Gabriele, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
Jensen, Axel, Velbert, GERMANY, FEDERAL REPUBLIC OF
Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Nickl, Werner, Waldkirch, GERMANY, FEDERAL REPUBLIC OF
Oehme, Felix, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schlemmer, Karl-Heinz, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Steinhagen, Henning, Suzlbach, GERMANY, FEDERAL REPUBLIC OF

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION:	US 20050075347	A1	20050407
	US 7125995	B2	20061024
APPLICATION INFO.:	US 2003-416622	A1	20031229 (10)
	WO 2001-EP12694		20011102

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10056312	20001114
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1654	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel amidoalkyl uracil derivatives of formula (I), to a method for the production thereof, and to their use as medicament active substances for the prophylaxis and/or treatment of medical disorders. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:133996 USPATFULL <<LOGINID::20101117>>

TITLE: Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays

INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Paffhausen, Wolfgang, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Schade, Andreas, Essen, GERMANY, FEDERAL REPUBLIC OF
Bechem, Martin, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Delf, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030092081	A1	20030515
	US 7138280	B2	20061121
APPLICATION INFO.:	US 2002-263607	A1	20021003 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-966522, filed on 28 Sep 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19621312	19960528
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KURT BRISCOE, NORRIS, MCLAUGHLIN & MARCUS, P.A., 220 EAST 42ND STREET, 30TH FLOOR, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	438	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4

already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:30956 USPATFULL <<LOGINID::20101117>>
 TITLE: Substituted amidoalkyl-uracils and their use
 INVENTOR(S): Harter, Michael, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
 Albrecht, Barbara, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
 Gerisch, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
 Handke, Gabriele, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
 Hutter, Joachim, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
 Jensen, Axel, Velbert, GERMANY, FEDERAL REPUBLIC OF
 Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
 Mittendorf, Joachim, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
 Oehme, Felix, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
 Schlemmer, Karl-Heinz, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
 Steinhagen, Henning, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030022905	A1	20030130
	US 6649618	B2	20031118
APPLICATION INFO.:	US 2001-906296	A1	20010716 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10034801	20000718
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jeffrey M. Greenman, Vice President, Patents and
Licensing, Bayer Corporation, 400 Morgan Lane, West
Haven, CT, 06516
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1738

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel amidoalkyl-uracil derivatives of the formula (I) ##STR1##

a process for their preparation and their use as medicaments for the
prophylaxis and/or treatment of disorders are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2002:37557 USPATFULL <<LOGINID::20101117>>

TITLE: MASKING BACKGROUND FLUORESCENCE AND
LUMINESCENCE IN OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

INVENTOR(S): KRAHN, THOMAS, HAGEN, GERMANY, FEDERAL
REPUBLIC OF
PAFFHAUSEN, WOLFGANG, LEVERKUSEN, GERMANY, FEDERAL
REPUBLIC OF
SCHADE, ANDREAS, ESSEN, GERMANY, FEDERAL REPUBLIC OF
BECHER, MARTIN, WUPPERTAL, GERMANY, FEDERAL REPUBLIC OF
SCHMIDT, DELF, WUPPERTAL, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020022274	A1	20020221
	US 6420183	B2	20020716
APPLICATION INFO.:	US 1998-194099	A1	19981120 (9)
	WO 1997-EP2662		19970523

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19621312	19960528
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NORRIS McLAUGHLIN & MARCUS, P.A., 220 EAST 42nd STREET 30TH FLOOR, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	462	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for the quantitative optical analysis of fluorescently
labelled biological cells 5, a cell layer on a transparent support at
the bottom 2 of a reaction vessel 1 is in contact with a solution 3
containing the fluorescent dye 4. The sensitivity of analytical
detection can be considerably improved if to the fluorescent dye 4
already present in addition a masking dye 9, which absorbs the
excitation light 6 for the fluorescent dye 4 and/or its emission light
7, is added to the solution 3 and/or if a separating layer 10 permeable
to the solution and absorbing and/or reflecting the excitation light 6
or the emission light 7 is applied to the cell layer at the bottom 2.
This process can also be used for improving the sensitivity in the
quantitative optical analysis of a luminescent biological cell layer.
The separating layer 10 must in this case be composed such that it has a
high power of reflection for the luminescent light 11. Analogously,
these process principles can also be used in receptor studies for the

masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2002:27123 USPATFULL <<LOGINID::20101117>>

TITLE: Masking background fluorescence and luminescence in optical analysis of biomedical assays

INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Paffhausen, Wolfgang, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Schade, Andreas, Essen, GERMANY, FEDERAL REPUBLIC OF
Bechem, Martin, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Delf, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020015969	A1	20020207
	US 7063952	B2	20060620
APPLICATION INFO.:	US 2001-966137	A1	20010928 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-194099, filed on 20 Nov 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19621312	19960528
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Kurt G. Briscoe, Norris McLaughlin & Marcus, P.A., 30th Floor, 220 East 42nd Street, New York, NY, 10017	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	462	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer.

The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2002:16874 USPATFULL <<LOGINID::20101117>>

TITLE: Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays

INVENTOR(S): Krahn, Thoams, Hagen, GERMANY, FEDERAL REPUBLIC OF
Paffhausen, Wolfgang, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Schade, Andreas, Essen, GERMANY, FEDERAL REPUBLIC OF
Bechem, Martin, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Delf, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020009754	A1	20020124
APPLICATION INFO.:	US 2001-966522	A1	20010928 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-194099, filed on 20 Nov 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19621312	19960528
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Kurt G. Briscoe, Norris McLaughlin & Marcus, P.A., 30th Floor, 220 East 42nd Street, New York, NY, 10017	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	462	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6

or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2. (FIGS. 2 and 10)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1997:805887 CAPLUS <<LOGINID::20101117>>
 DOCUMENT NUMBER: 128:59162
 ORIGINAL REFERENCE NO.: 128:11503a,11506a
 TITLE: Masking background fluorescence and luminescence in optical analysis of biomedical assays
 INVENTOR(S): Krahn, Thomas; Paffhausen, Wolfgang; Schade, Andreas; Bechem, Martin; Schmidt, Delf
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; Krahn, Thomas; Paffhausen, Wolfgang; Schade, Andreas; Bechem, Martin; Schmidt, Delf
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9745739	A1	19971204	WO 1997-EP2662	19970523
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19621312	A1	19971204	DE 1996-19621312	19960528
CA 2256629	A1	19971204	CA 1997-2256629	19970523
CA 2256629	C	20030722		
EP 906572	A1	19990407	EP 1997-927032	19970523
EP 906572	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, FI				
JP 2000512746	T	20000926	JP 1997-541578	19970523
JP 3452068	B2	20030929		
AT 215698	T	20020415	AT 1997-927032	19970523
ES 2175416	T3	20021116	ES 1997-927032	19970523
US 20020022274	A1	20020221	US 1998-194099	19981120
US 6420183	B2	20020716		
US 20020009754	A1	20020124	US 2001-966522	20010928
US 20020015969	A1	20020207	US 2001-966137	20010928
US 7063952	B2	20060620		


```

=> dup rem l4
PROCESSING COMPLETED FOR L4
L6          27 DUP REM L4 (8 DUPLICATES REMOVED)

=> s l4 and masking
L7          9 L4 AND MASKING

=> d l7 1-9 ti

L7  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2010 ACS on STN
TI  Masking background fluorescence and luminescence in optical
    analysis of biomedical assays

L7  ANSWER 2 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI  Masking background fluorescence and luminescence in the optical
    analysis of biomedical assays.

L7  ANSWER 3 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI  Masking of the background fluorescence and luminescence in the
    optical analysis of biomedical assays.

L7  ANSWER 4 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI  Masking background fluorescence and luminescence in optical
    analysis of biomedical assays.

L7  ANSWER 5 OF 9  USPATFULL on STN
TI  MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
    OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L7  ANSWER 6 OF 9  USPATFULL on STN
TI  Masking of the background fluorescence and luminescence in the
    optical analysis of biomedical assays

L7  ANSWER 7 OF 9  USPATFULL on STN
TI  MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
    ANALYSIS OF BIOMEDICAL ASSAYS

L7  ANSWER 8 OF 9  USPATFULL on STN
TI  Masking background fluorescence and luminescence in optical
    analysis of biomedical assays

L7  ANSWER 9 OF 9  USPATFULL on STN
TI  Masking of the background fluorescence and luminescence in the
    optical analysis of biomedical assays

=> e schade andreas/au
E1          8      SCHADE ANDRE/AU
E2          2      SCHADE ANDRE FRIEDRICH ALEXANDER UNIVERSITAT ERLANGEN/AU
E3         47 --> SCHADE ANDREAS/AU
E4          3      SCHADE ANDREW/AU
E5         53      SCHADE ANDREW E/AU
E6          1      SCHADE ANDREW EDWARD/AU
E7          2      SCHADE ANJA/AU
E8          3      SCHADE ANNE L/AU
E9         11      SCHADE ANNEMIEK/AU
E10         1      SCHADE ANNIKA/AU
E11         1      SCHADE ANNIKA I/AU
E12        2      SCHADE ARLEN R/AU

```



```

=> s e3
L8          47 "SCHADE ANDREAS"/AU

=> s l8 and masking
L9          9 L8 AND MASKING

=> d l9 1-9 ti

L9  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2010 ACS on STN
TI  Masking background fluorescence and luminescence in optical
    analysis of biomedical assays

L9  ANSWER 2 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI  Masking background fluorescence and luminescence in the optical
    analysis of biomedical assays.

L9  ANSWER 3 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI  Masking of the background fluorescence and luminescence in the
    optical analysis of biomedical assays.

L9  ANSWER 4 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI  Masking background fluorescence and luminescence in optical
    analysis of biomedical assays.

L9  ANSWER 5 OF 9  USPATFULL on STN
TI  MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
    OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L9  ANSWER 6 OF 9  USPATFULL on STN
TI  Masking of the background fluorescence and luminescence in the
    optical analysis of biomedical assays

L9  ANSWER 7 OF 9  USPATFULL on STN
TI  MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
    ANALYSIS OF BIOMEDICAL ASSAYS

L9  ANSWER 8 OF 9  USPATFULL on STN
TI  Masking background fluorescence and luminescence in optical
    analysis of biomedical assays

L9  ANSWER 9 OF 9  USPATFULL on STN
TI  Masking of the background fluorescence and luminescence in the
    optical analysis of biomedical assays

=> e bechem martin/au
E1          9      BECHEM KLAUS/AU
E2          83     BECHEM M/AU
E3          125 --> BECHEM MARTIN/AU
E4          1      BECHEM MARTIN DIPL BIOL/AU
E5          1      BECHEM N N/AU
E6          7      BECHEM PHILIP/AU
E7          1      BECHEM PHILIP C/AU
E8          2      BECHEM PHILIP CARL/AU
E9          1      BECHEM PHILLIP/AU
E10         12     BECHEM ULRICH/AU
E11         1      BECHEM ULRICH W/AU
E12         2      BECHEM ULRICH WILHELM/AU

=> s e2-e3
L10         208 ("BECHEM M"/AU OR "BECHEM MARTIN"/AU)

```

```

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11      156 DUP REM L10 (52 DUPLICATES REMOVED)

=> s l11 and masking
L12      10 L11 AND MASKING

=> d l12 1-10 ti

L12 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
TI Masking background fluorescence and luminescence in optical
analysis of biomedical assays

L12 ANSWER 2 OF 10 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking background fluorescence and luminescence in the optical
analysis of biomedical assays.

L12 ANSWER 3 OF 10 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking of the background fluorescence and luminescence in the
optical analysis of biomedical assays.

L12 ANSWER 4 OF 10 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking background fluorescence and luminescence in optical
analysis of biomedical assays.

L12 ANSWER 5 OF 10 USPATFULL on STN
TI MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L12 ANSWER 6 OF 10 USPATFULL on STN
TI Quinoxalinones and their use especially in the treatment of
cardiovascular diseases

L12 ANSWER 7 OF 10 USPATFULL on STN
TI Masking of the background fluorescence and luminescence in the
optical analysis of biomedical assays

L12 ANSWER 8 OF 10 USPATFULL on STN
TI MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
ANALYSIS OF BIOMEDICAL ASSAYS

L12 ANSWER 9 OF 10 USPATFULL on STN
TI Masking background fluorescence and luminescence in optical
analysis of biomedical assays

L12 ANSWER 10 OF 10 USPATFULL on STN
TI Masking of the background fluorescence and luminescence in the
optical analysis of biomedical assays

=> e schmidt delf/au
E1      1 SCHMIDT DELBERT D/AU
E2      1 SCHMIDT DELBERT L/AU
E3      221 --> SCHMIDT DELF/AU
E4      2 SCHMIDT DELF D/AU
E5      1 SCHMIDT DELFT/AU
E6      1 SCHMIDT DELT/AU
E7      7 SCHMIDT DENISE/AU
E8      3 SCHMIDT DENISE A/AU
E9      3 SCHMIDT DENISE RODRIGUES COSTA/AU

```

E10 4 SCHMIDT DENISE S/AU
E11 2 SCHMIDT DENISE Z/AU
E12 53 SCHMIDT DENNIS/AU

=> s e3 and masking

L13 9 "SCHMIDT DELF"/AU AND MASKING

=> dup rem l13

PROCESSING COMPLETED FOR L13

L14 9 DUP REM L13 (0 DUPLICATES REMOVED)

=> d l14 1-9 ti

L14 ANSWER 1 OF 9 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking background fluorescence and luminescence in the optical
analysis of biomedical assays.

L14 ANSWER 2 OF 9 USPATFULL on STN
TI MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L14 ANSWER 3 OF 9 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking of the background fluorescence and luminescence in the
optical analysis of biomedical assays.

L14 ANSWER 4 OF 9 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking background fluorescence and luminescence in optical
analysis of biomedical assays.

L14 ANSWER 5 OF 9 USPATFULL on STN
TI Masking of the background fluorescence and luminescence in the
optical analysis of biomedical assays

L14 ANSWER 6 OF 9 USPATFULL on STN
TI MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
ANALYSIS OF BIOMEDICAL ASSAYS

L14 ANSWER 7 OF 9 USPATFULL on STN
TI Masking background fluorescence and luminescence in optical
analysis of biomedical assays

L14 ANSWER 8 OF 9 USPATFULL on STN
TI Masking of the background fluorescence and luminescence in the
optical analysis of biomedical assays

L14 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
TI Masking background fluorescence and luminescence in optical
analysis of biomedical assays

=> logoff y

(FILE 'HOME' ENTERED AT 14:57:48 ON 17 NOV 2010)

FILE 'CAPLUS, MEDLINE, BIOSIS, BIOTECHNO, COMPENDEX, ANABSTR, CERAB,
METADEX, USPATFULL' ENTERED AT 14:58:11 ON 17 NOV 2010

E KRAHN THOMAS/AU

L1 140 SEA FILE=MFE SPE=ON ABB=ON PLU=ON ("KRAHN THOAMS"/AU OR
"KRAHN THOMAS"/AU)

L2 16 SEA FILE=MFE SPE=ON ABB=ON PLU=ON L1 AND MASKING

L3 16 DUP REM L2 (0 DUPLICATES REMOVED)

D L3 1-16 TI
 D L3 1-5 IBIB ABS
 D L3 7-16 IBIB ABS
 E PAFFHAUSEN WOLFGANG/AU
 L4 35 SEA FILE=MFE SPE=ON ABB=ON PLU=ON ("PAFFHAUSEN W"/AU OR
 "PAFFHAUSEN WOLFGANG"/AU)
 L5 9 SEA FILE=MFE SPE=ON ABB=ON PLU=ON L4 AND MASKING
 L6 27 DUP REM L4 (8 DUPLICATES REMOVED)
 L7 9 SEA FILE=MFE SPE=ON ABB=ON PLU=ON L4 AND MASKING
 D L7 1-9 TI
 E SCHADE ANDREAS/AU
 L8 47 SEA FILE=MFE SPE=ON ABB=ON PLU=ON "SCHADE ANDREAS"/AU
 L9 9 SEA FILE=MFE SPE=ON ABB=ON PLU=ON L8 AND MASKING
 D L9 1-9 TI
 E BECHEM MARTIN/AU
 L10 208 SEA FILE=MFE SPE=ON ABB=ON PLU=ON ("BECHEM M"/AU OR "BECHEM
 MARTIN"/AU)
 L11 156 DUP REM L10 (52 DUPLICATES REMOVED)
 L*** DEL 71 S E2-E3
 L*** DEL 17 S E2-E3
 L*** DEL 63 S E2-E3
 L*** DEL 54 S E2-E3
 L*** DEL 54 S E2-E3
 L*** DEL 54 S E2-E3
 L*** DEL 54 S E2-E3
 L*** DEL 54 S E2-E3
 L*** DEL 54 S E2-E3
 L12 10 SEA FILE=MFE SPE=ON ABB=ON PLU=ON L11 AND MASKING
 D L12 1-10 TI
 E SCHMIDT DELF/AU
 L13 9 SEA FILE=MFE SPE=ON ABB=ON PLU=ON "SCHMIDT DELF"/AU AND
 MASKING
 L14 9 DUP REM L13 (0 DUPLICATES REMOVED)
 D L14 1-9 TI

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	85.22	85.44
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.85	-0.85

STN INTERNATIONAL LOGOFF AT 15:03:41 ON 17 NOV 2010